Dataset Information

Semi-quantitative measurements of chemokine receptor 4-targeted ⁶⁸Ga-pentixafor PET/CT in response assessment of Waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma.

ABSTRACT:

Purpose

⁶⁸Ga-pentixafor PET/CT was reported to have a high sensitivity in detecting tumor involvement of Waldenström macroglobulinemia/lymphoplasmacytic lymphoma (WM/LPL) in our previous study. We aimed to further investigate the semi-quantitative measurements of ⁶⁸Ga-pentixafor PET/CT in response assessment in WM/LPL.

Methods

Fifteen patients with WM/LPL were recruited in a prospective cohort study and underwent both ⁶⁸Ga-pentixafor and ¹⁸F-FDG PET/CT at baseline and post-treatment. PET/CT-based responses were analyzed with semi-quantitative assessments of metabolic tumor volume (MTV) and total lesions glycolysis/uptake (TLG_FDG and TLU_CXCR4), and the correlation between PET/CT-based response and clinical response, monoclonal protein and IgM response was analyzed.

Results

After chemotherapy, 5 patients had complete response or very good partial response, 8 had partial response or minimal response and 2 had progressive disease. In quantitative analysis, ⁶⁸Ga-pentixafor PET/CT-based response (measured in ∆TLU_CXCR4%, ∆MTV_CXCR4%, ∆SUVpeak%) showed a significant direct correlation with clinical response, monoclonal protein and IgM response (p < 0.01). However, ¹⁸F-FDG PET/CT-based response was independent from clinical response (p > 0.05).

Conclusions

The semi-quantitative measurements of ⁶⁸Ga-pentixafor PET/CT outperformed ¹⁸F-FDG PET/CT in response assessment of WM/LPL.

SUBMITTER: Pan Q

PROVIDER: S-EPMC8556471 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Semi-quantitative measurements of chemokine receptor 4-targeted <sup>68</sup>Ga-pentixafor PET/CT in response assessment of Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.

Pan Qingqing Q Cao Xinxin X Luo Yaping Y Li Jian J Li Fang F

EJNMMI research 20211029 1

<h4>Purpose</h4><sup>68</sup>Ga-pentixafor PET/CT was reported to have a high sensitivity in detecting tumor involvement of Waldenström macroglobulinemia/lymphoplasmacytic lymphoma (WM/LPL) in our previous study. We aimed to further investigate the semi-quantitative measurements of <sup>68</sup>Ga-pentixafor PET/CT in response assessment in WM/LPL.<h4>Methods</h4>Fifteen patients with WM/LPL were recruited in a prospective cohort study and underwent both <sup>68</sup>Ga-pentixafor and <sup>18</s ...[more]

PMID: 34714390

Similar Datasets

Project description:PurposeThis study aimed to explore the significance of 68Ga-pentixafor PET/CT in guiding surgical treatments for primary aldosteronism (PA) patients, by identifying functional lesions and determining the dominant side of aldosterone secretion.Materials and methodsWe prospectively included 91 PA patients receiving surgical treatments based on the results of 68Ga-pentixafor PET/CT. The 68Ga-pentixafor PET/CT images were evaluated by visual and semi-quantitative analysis. The relationship between radionuclide imaging characteristics and postoperative outcomes was assessed following surgery.ResultsThe positive detection rate of 68Ga-pentixafor PET/CT in 91 PA patients was 85.7 % (78/91) with a median maximum standardized uptake value (SUVmax) of 10.2 (6.0-16.0). The SUVmax was positively correlated with lesion diameter (r = 0.497, P < 0.001), while negatively correlated with the blood potassium level (r = -0.450, P < 0.001) and plasma renin activity (r = -0.297, P = 0.004). 63 cases of 73 PA patients with unilateral adrenal lesion were identified positive by 68Ga-pentixafor PET/CT, and 95.2 % of the 63 positive cases benefited from surgical resection of the identified positive lesions. Among 18 PA patients with bilateral lesions, 68Ga-pentixafor PET/CT identified positive lesions in 15 cases, and 86.7 % (13/15) of the positive cases benefited from total or partial adrenalectomy guided by 68Ga-pentixafor PET/CT. There was no significant difference in postoperative outcomes between patients undergoing partial adrenalectomy with those subjected to total adrenalectomy. The accuracy rate of 68Ga-pentixafor PET/CT in determining the dominant side of aldosterone secretion for PA was 85.7 %, which was comparable to the 71.4 % of adrenal vein sampling (AVS).Conclusions68Ga-pentixafor PET/CT could effectively guide the surgical management for PA patients, achieving favorable postoperative outcomes. The accuracy rate of 68Ga-pentixafor PET/CT in identifying the dominant side of aldosterone secretion was not inferior to that of AVS.

Project description:PurposeThe chemokine receptor CXCR4 is a promising target for molecular imaging of CXCR4+ cell types, e.g. inflammatory cells, in cardiovascular diseases. We speculated that a specific CXCR4 ligand, [68Ga]pentixafor, along with novel techniques for motion correction, would facilitate the in vivo characterization of CXCR4 expression in small culprit and nonculprit coronary atherosclerotic lesions after acute myocardial infarction by motion-corrected targeted PET/CT.MethodsCXCR4 expression was analysed ex vivo in separately obtained arterial wall specimens. [68Ga]Pentixafor PET/CT was performed in 37 patients after stent-based reperfusion for a first acute ST-segment elevation myocardial infarction. List-mode PET data were reconstructed to five different datasets using cardiac and/or respiratory gating. Guided by CT for localization, the PET signals of culprit and various groups of nonculprit coronary lesions were analysed and compared.ResultsEx vivo, CXCR4 was upregulated in atherosclerotic lesions, and mainly colocalized with CD68+ inflammatory cells. In vivo, elevated CXCR4 expression was detected in culprit and nonculprit lesions, and the strongest CXCR4 PET signal (median SUVmax 1.96; interquartile range, IQR, 1.55-2.31) was observed in culprit coronary artery lesions. Stented nonculprit lesions (median SUVmax 1.45, IQR 1.23-1.88; P = 0.048) and hot spots in naive remote coronary segments (median SUVmax 1.34, IQR 1.23-1.74; P = 0.0005) showed significantly lower levels of CXCR4 expression. Dual cardiac/respiratory gating provided the strongest CXCR4 PET signal and the highest lesion detectability.ConclusionWe demonstrated the basic feasibility of motion-corrected targeted PET/CT imaging of CXCR4 expression in coronary artery lesions, which was triggered by vessel wall inflammation but also by stent-induced injury. This novel methodology may serve as a platform for future diagnostic and therapeutic clinical studies targeting the biology of coronary atherosclerotic plaque.

Dataset Information

Semi-quantitative measurements of chemokine receptor 4-targeted ⁶⁸Ga-pentixafor PET/CT in response assessment of Waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma.

Purpose

Methods

Results

Conclusions

Publications

Semi-quantitative measurements of chemokine receptor 4-targeted <sup>68</sup>Ga-pentixafor PET/CT in response assessment of Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets

Dataset Information

Semi-quantitative measurements of chemokine receptor 4-targeted 68Ga-pentixafor PET/CT in response assessment of Waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma.

Purpose

Methods

Results

Conclusions

Publications

Semi-quantitative measurements of chemokine receptor 4-targeted <sup>68</sup>Ga-pentixafor PET/CT in response assessment of Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets

Semi-quantitative measurements of chemokine receptor 4-targeted ⁶⁸Ga-pentixafor PET/CT in response assessment of Waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma.